Name: 글로벌 시장 동향
SKU: PH7165
Availability: InStock

보고서 요약(국문)

개요
전 세계 알파-1 항트립신 결핍증 치료(AAT) 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 알파-1 항트립신 결핍증 치료 시장은 여러 요인의 영향으로 지난 몇 년간 상당한 성장과 변화를 경험해 왔습니다. AAT 결핍증이 있는 사람은 폐 질환을 비롯한 여러 질병에 걸릴 위험이 높아집니다. AAT는 간에서 생성되는 단백질로 폐를 보호하는 역할을 합니다. 체내에서 AAT가 충분히 생성되지 않으면 흡연, 대기 오염, 환경 먼지 등으로 인한 폐 손상에 더욱 취약해집니다.
특히 개발도상국을 중심으로 한 정부 투자와 연구는 첨단 제품 또는 치료법의 활용을 촉진하고 전 세계 알파-1 항트립신 결핍증 치료 시장의 성장을 견인할 것입니다. 이러한 혁신적인 제품에는 증상 관리를 위한 증강 요법과 같은 새로운 치료법이 포함됩니다.

시장 동향: 성장 동력 및 제약 요인
증강 요법에 대한 규제 승인 증가
선진국들은 높은 투자, 소득 수준 및 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 알파-1 항트립신 결핍증 치료에 대한 수요가 연구 결과의 긍정적인 결과로 인해 상당 부분 증가했습니다. 각국의 제품 출시 관련 규제 승인은 시장 성장을 견인하는 중요한 요인이 될 것입니다.
희귀 및 중증 질환 치료제를 보유한 글로벌 바이오제약 기업인 카마다(Kamada Ltd.)의 보고서에 따르면, 2023년 5월 16일 글래시아(Glassia) [알파-1 프로테아제 억제제(인간 유래)]가 스위스에서 중증 유전성 알파-1 항트립신 결핍증(AA)으로 인한 폐기종 성인 환자의 장기 증강 및 유지 치료에 대한 시판 승인을 받았습니다.
또한, 알파-1 항트립신 결핍증 관리를 위한 새로운 치료법 또는 약물의 활용이 증가하고 있습니다. 사람들의 인식 제고와 혁신적인 제품 개발을 위한 연구 증가는 알파-1 항트립신 결핍 치료 시장 성장을 이끄는 주요 요인이 될 것입니다.
증강 요법과 관련된 부작용
알파-1 항트립신 결핍 환자에게서 증강 요법의 몇 가지 부작용이 보고되었지만, 대다수는 심각한 문제를 경험하지 않습니다. 가장 흔한 부작용은 피로감이나 독감 유사 증상으로, 주입 후 최대 24시간 동안 지속될 수 있습니다. 주입 속도를 늦추면 이러한 증상이 감소하거나 사라지는 경우가 많습니다.
가려움증, 발진, 두드러기, 호흡곤란, 가슴 답답함, 천명음은 일부 알파-1 항트립신 결핍 환자에게서 나타나는 가벼운 알레르기 반응과 유사한 증상입니다. 환자가 주입 전에 베나드릴과 같은 항히스타민제를 복용하면 많은 환자가 증강 요법을 계속 받을 수 있습니다. 매우 드물게, 부작용이 너무 심해서 알파-1 항트립신 결핍 환자가 증강 요법 약물 복용을 완전히 중단하는 경우도 있습니다.

시장 세분화 분석
전 세계 알파-1 항트립신 결핍 치료 시장은 치료 유형, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.
증강 요법 부문은 시장 점유율의 약 43%를 차지했습니다.
알파-1 항트립신(AAT) 결핍이 심각한 폐기종 환자는 증강 요법(때로는 대체 요법이라고도 함)의 혜택을 받을 수 있습니다. AAT 결핍 환자의 폐에서 AAT 수치는 건강한 기증자의 혈액에서 얻은 알파-1 항트립신 단백질을 사용하여 증가합니다. AAT는 건강한 사람의 면역 체계로 인한 폐 손상을 방지합니다. AAT 증강 요법은 AAT 결핍 환자가 폐에서 AAT 양을 늘려 추가적인 폐 손상을 예방하는 데 도움을 줍니다.

세계적인 혈장 유래 의약품 제조업체인 그리폴스(Grifols)에 따르면, 2023년 7월 13일, 알파-1-안티트립신(AAT) 결핍증(알파-1)으로 인한 폐기종 환자에게 그리폴스 프로라스틴-C를 두 가지 용량으로 주 1회 투여했을 때 폐 조직 손실 속도가 더 완만해지는지 확인하기 위한 3상 임상 시험이 목표 환자 수인 339명을 달성했습니다.
현재까지 진행된 AAT 증강 치료에 대한 최대 규모의 무작위 배정, 위약 대조, 이중 맹검 연구인 SPARTA에 따르면, 프로라스틴-C는 두 가지 효과적인 용량으로 주 1회 투여하여 AAT 단백질 수치를 증가시킴으로써 알파-1 결핍 환자의 폐기종 진행 속도를 상당히 늦출 가능성이 있습니다.

지리적 시장 침투
북미는 2022년 시장 점유율의 약 38%를 차지했습니다.
의료 분야에서 알파-1 항트립신 결핍증 치료에 대한 수요가 증가함에 따라 북미 제조업체들은 사업 확장의 기회를 얻고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 알파-1 항트립신 결핍증 치료에 대한 수요를 견인하고 있습니다.
의료비 지출 증가, 연구 활동 확대, 기술 발전, 다양한 치료법 개발, 그리고 이 지역 전반에 걸친 제약 및 생명공학 기업 설립 증가는 알파-1 항트립신 결핍증 치료 시장 점유율 성장에 기여하고 있습니다. 프로라스틴-C와 같은 다양한 혁신적인 치료법에 대한 인식이 높아짐에 따라 이 지역 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계 시장에서 주도적인 위치를 차지하고 있음을 더욱 뒷받침합니다.
북미는 미국을 중심으로 글로벌 알파-1 항트립신 결핍증 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 정부의 인프라 개발 및 투자 촉진 정책과 첨단 기술 발전에 대한 관심은 미국 내 알파-1 항트립신 결핍증 치료제 수요를 견인했습니다. 미국은 알파-1 항트립신 결핍증 치료제 수요를 촉진하는 여러 정책을 적극적으로 추진해 왔습니다.
코로나19 영향 분석
2019년 말 발생한 코로나19 팬데믹은 전 세계 산업, 특히 알파-1 항트립신 결핍증 치료제 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄 조치, 공급망 차질, 경제 활동 위축에 직면하면서 다양한 의료기기의 주요 소비자인 제약 부문은 큰 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치는 전 세계적으로 여러 사업에 영향을 미쳤습니다.
주요 의료기기 산업은 생산이 중단되고 코로나19 관리에 집중하면서 알파-1 항트립신 결핍증 치료제 수요가 급감했습니다. 현재 여러 연구가 시작되었고, 기업들은 제품의 안전성과 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로, 전 세계 알파-1 항트립신 결핍증 치료 시장에 대한 팬데믹의 영향은 비교적 완만할 것으로 예상되며, 알파-1 항트립신 결핍증 관리를 위한 증강 요법 및 기타 프로그램과 같은 새로운 치료법에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.
주요 개발 사항
• 2023년 5월 23일, 희귀 질환 전문 임상 단계 바이오제약 기업인 메레오 바이오파마 그룹(Mereo BioPharma Group plc)은 알파-1 항트립신 결핍증 관련 폐 질환(AATD-LD) 관리를 위한 알벨레스타트의 2상 "아스트라우스(ASTRAEUS)" 연구 데이터와 알벨레스타트 사용 시 바이오마커 감소와 중요한 환자 보고 결과(PRO) 지표인 SGRQ 향상 간의 연관성을 보여주는 사후 분석 결과를 과학계에 최초로 발표했습니다.

• 2023년 1월 9일, 다케다 제약과 애로우헤드 제약은 알파-1 항트립신 결핍증(AATD-LD)으로 인한 간 질환 관리를 위한 임상시험용 약물 파지르시란(TAK-999/ARO-AAT)의 2상 SEQUOIA 연구의 주요 결과를 발표했습니다. 또한, 다케다와 애로우헤드가 공동으로 개발하고 다케다가 수행할 3상 임상시험 계획도 함께 공개했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 카마다 제약, 다케다 제약, CSL, 버텍스 제약, 그리폴스, 애로우헤드 제약, 다이서나 제약, 인히브릭스, 웨이브 라이프 사이언스, 메레오 바이오파마 그룹 등이 있습니다.
보고서 구매 이유

• 치료법, 투여 경로, 최종 사용자 및 지역별로 세분화된 글로벌 알파-1 항트립신 결핍증 치료제 시장을 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 알파-1 항트립신 결핍증 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 알파-1 항트립신 결핍증 치료제 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Alpha-1 Antitrypsin Deficiency Therapy (AAT) Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global alpha-1 antitrypsin deficiency therapy market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The chance of developing lung and additional illnesses increases if the person have an AAT deficiency. AAT is a protein produced in the liver that aids in lung defense. The lungs are more vulnerable to injury from smoking, air pollution, and environmental dust if the body fails to produce enough AAT.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or therapies and boost the global alpha-1 antitrypsin deficiency therapy market. The respective innovative products includes the use of novel treatments such as augmentation therapy for better management.
Market Dynamics: Drivers & Restraints
Growing regulatory approvals for augmentation therapy
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for alpha-1 antitrypsin deficiency therapy owing to the positive outcomes in research. Various regulatory approvals for product launch among different countries will be a crucial factor driving the growth of the market.
On May 16, 2023, Glassia [Alpha-1 Proteinase Inhibitor (Human)] got approval for marketing in Switzerland for long-term augmentation along with maintenance treatment in adults having clinically diagnosed emphysema caused by severe hereditary Alpha-1 antitrypsin deficiency (AA), according to a report from Kamada Ltd., a commercial phase global biopharmaceutical business with a portfolio of marketed drugs indicated for rare and severe medical conditions.
Furthermore, the rising utilization of novel therapies or drugs for the management of alpha-1 antitrypsin deficiency. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the alpha-1 antitrypsin deficiency therapys market.
Side effects associated with the augmentation therapy
Although several negative effects of augmentation therapy have been recorded by alphas, the majority never experience any serious issues. The most frequent adverse reaction is fatigue or flu-like symptoms, which can persist for as long as 24 hours following an infusion. Slowing down the pace of infusion can frequently decrease or even get rid of these symptoms.
Itching, rash, hives, dyspnea, tightness in the chest, and wheezing are some of the symptoms that some Alphas have that resemble mild allergic reactions. If patients take an antihistamine like Benadryl prior to their infusions, many of those can continue getting augmentation therapy. Very seldom, adverse effects are bad enough to have an Alpha completely quit their augmentation medication.
Segment Analysis
The global alpha-1 antitrypsin deficiency therapy market is segmented based on therapy, route of administration, end user and region.
Augmentation Therapy segment accounted for approximately 43% of market share
Patients with significant alpha-1 antitrypsin (AAT) insufficiency who have emphysema may benefit from augmentation therapy, sometimes referred to as replacement therapy. The level of alpha-1 antitrypsin (AAT) in the lungs of patients having AAT deficiency is increased using alpha-1 antitrypsin protein obtained from the blood of healthy donors. AAT guards against lung damage caused by the immune system in healthy people. AAT augmentation therapy helps individuals with AAT deficiency increase the quantity of AAT in their lungs, preventing additional lung damage.
On July 13, 2023, a phase 3 clinical trial to ascertain whether alpha-1-antitrypsin (AAT) deficiency (alpha-1) individuals who have emphysema have a more gradual rate of lung tissue lack when handled weekly with two distinct dose regimens of Grifols Prolastin-C has reached its enrollment goal of 339 patients, according to Grifols, one of the world's top producers of plasma-derived medications.
Prolastin-C has the potential to substantially slow the development of emphysema in alpha-1 patients by increasing AAT protein levels via weekly administration of two successful dose levels compared to placebo, according to SPARTA, the largest randomized, placebo-controlled, double-blind, study on AAT augmentation treatment to date.
Geographical Penetration
North America accounted for around 38% of market share in 2022
Due to the rising need for alpha-1 antitrypsin deficiency therapy in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for alpha-1 antitrypsin deficiency therapy.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of therapies for management, and increase in pharmaceutical or biotechnology business establishment across the region are also contributing to the growth of alpha-1 antitrypsin deficiency therapy market share of this region. The market in this area is growing as people become more aware of various novel innovative therapies such as Prolastin-C. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global alpha-1 antitrypsin deficiency therapy market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for alpha-1 antitrypsin deficiency therapy in the U.S. United States have been proactive in executing several initiatives or researches, stimulating alpha-1 antitrypsin deficiency therapy demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global alpha-1 antitrypsin deficiency therapy market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for alpha-1 antitrypsin deficiency therapy. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global alpha-1 antitrypsin deficiency therapy market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like augmenting therapies and other programs for management of alpha-1 antitrypsin deficiency.
Key Developments
• On May 23, 2023, data about the Phase 2 "ASTRAEUS" investigation of alvelestat for the management of Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD), along with post-hoc analyses illustrating the association among biomarker reductions using alvelestat and enhancements in SGRQ, a significant Patient-Reported Results (PRO) measure, have been presented for the very first time to the scientific world by Mereo BioPharma Group plc, a clinical-stage biopharmaceutical business focused on rare diseases.
• On January 9, 2023, topline findings from the Phase 2 SEQUOIA research trial of the investigational drug fazirsiran (TAK-999/ARO-AAT) for the management of liver disease brought on by alpha-1 antitrypsin deficiency (AATD-LD) were disclosed by Takeda and Arrowhead Pharmaceuticals Inc. A Phase 3 study that was created jointly by Takeda and Arrowhead and would be carried out by Takeda was also outlined by the firms.
Competitive Landscape
The major global players in the market include Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Inhibrx, Inc., Wave Life Sciences and Mereo Biopharma Group PLC among others.
Why Purchase the Report?
• To visualize the global alpha-1 antitrypsin deficiency therapy market segmentation based on therapy, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of alpha-1 antitrypsin deficiency therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global alpha-1 antitrypsin deficiency therapy market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing regulatory approvals for augmentation therapy
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the augmentation therapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pricing Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. Russia-Ukraine War Impact Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Therapy
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.1.2. Market Attractiveness Index, By Therapy
7.2. Augmentation Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Prolastin-C
7.2.4. Aralast
7.2.5. Zemaira
7.2.6. Glassia
7.3. Medication
7.3.1. Bronchodilators
7.3.1.1. Ipratropium Bromide
7.3.1.2. Theophylline
7.3.2. Antibiotics
7.3.2.1. Doxycycline
7.3.2.2. Dapsone
7.4. Oxygen Therapy
7.5. Smoking Cessation Therapy
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Inhaled *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Kamada Pharmaceuticals*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Takeda Pharmaceutical Company Limited
12.3. CSL
12.4. Vertex Pharmaceuticals Incorporated
12.5. Grifols
12.6. Arrowhead Pharmaceuticals, Inc.
12.7. Dicerna Pharmaceuticals, Inc.
12.8. Inhibrx, Inc.
12.9. Wave Life Sciences
12.10. Mereo Biopharma Group PLC
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Kamada Pharmaceuticals, 4. Key Developments, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Inhibrx, Inc., Wave Life Sciences, Mereo Biopharma Group PLC

표 목록 (Tables)

List of Tables

Table 1 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 7 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Region, 2021-2030 (US$ Million)

Table 13 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 14 North America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 18 South America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 22 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Kamada Pharmaceuticals: Overview

Table 33 Kamada Pharmaceuticals: Product Portfolio

Table 34 Kamada Pharmaceuticals: Key Developments

Table 35 Takeda Pharmaceutical Company Limited: Overview

Table 36 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 37 Takeda Pharmaceutical Company Limited: Key Developments

Table 38 CSL: Overview

Table 39 CSL: Product Portfolio

Table 40 CSL: Key Developments

Table 41 Vertex Pharmaceuticals Incorporated: Overview

Table 42 Vertex Pharmaceuticals Incorporated: Product Portfolio

Table 43 Vertex Pharmaceuticals Incorporated: Key Developments

Table 44 Grifols: Overview

Table 45 Grifols: Product Portfolio

Table 46 Grifols: Key Developments

Table 47 Arrowhead Pharmaceuticals, Inc.: Overview

Table 48 Arrowhead Pharmaceuticals, Inc.: Product Portfolio

Table 49 Arrowhead Pharmaceuticals, Inc.: Key Developments

Table 50 Dicerna Pharmaceuticals, Inc.: Overview

Table 51 Dicerna Pharmaceuticals, Inc.: Product Portfolio

Table 52 Dicerna Pharmaceuticals, Inc.: Key Developments

Table 53 Inhibrx, Inc.: Overview

Table 54 Inhibrx, Inc.: Product Portfolio

Table 55 Inhibrx, Inc.: Key Developments

Table 56 Wave Life Sciences: Overview

Table 57 Wave Life Sciences: Product Portfolio

Table 58 Wave Life Sciences: Key Developments

Table 59 Mereo Biopharma Group PLC: Overview

Table 60 Mereo Biopharma Group PLC: Product Portfolio

Table 61 Mereo Biopharma Group PLC: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 2 Global Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 3 Global Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Alpha-1 Antitrypsin Deficiency Therapy Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Alpha-1 Antitrypsin Deficiency Therapy Market Y-o-Y Growth, By Therapy, 2022-2030 (%)

Figure 7 Augmentation Therapy in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 8 Medication Therapy in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 9 Oxygen Therapy in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 10 Smoking Cessation Therapy in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 11 Others Therapy in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 12 Global Alpha-1 Antitrypsin Deficiency Therapy Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Inhaled Route of Administration in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 14 Intravenous in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million

Figure 15 Global Alpha-1 Antitrypsin Deficiency Therapy Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 16 Hospitals End User in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 17 Ambulatory Surgical Centers End User in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 18 Others End User in Global Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 19 Global Alpha-1 Antitrypsin Deficiency Therapy Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 21 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 22 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 23 South America Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 24 Middle East and Africa Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 25 North America Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 26 North America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 27 North America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 28 North America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By End User, 2022 & 2030 (%)

Figure 29 North America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 30 South America Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 31 South America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 32 South America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 South America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By End User, 2022 & 2030 (%)

Figure 34 South America Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 35 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 36 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 37 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Share, By End User, 2022 & 2030 (%)

Figure 39 Europe Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 40 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 41 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 42 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 43 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Share, By End User, 2022 & 2030 (%)

Figure 44 Asia-Pacific Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 45 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Value, 2021-2030 (US$ Million)

Figure 46 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 47 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Middle East & Africa Alpha-1 Antitrypsin Deficiency Therapy Market Share, By End User, 2022 & 2030 (%)

Figure 49 Kamada Pharmaceuticals: Financials

Figure 50 Takeda Pharmaceutical Company Limited: Financials

Figure 51 CSL: Financials

Figure 52 Vertex Pharmaceuticals Incorporated: Financials

Figure 53 Grifols: Financials

Figure 54 Arrowhead Pharmaceuticals, Inc.: Financials

Figure 55 Dicerna Pharmaceuticals, Inc.: Financials

Figure 56 Inhibrx, Inc.: Financials

Figure 57 Wave Life Sciences: Financials

Figure 58 Mereo Biopharma Group PLC: Financials

글로벌 알파-1 항트립신 결핍 치료 시장 -2023-2030

Global Alpha-1 Antitrypsin Deficiency Therapy Market -2023-2030